¼¼°èÀÇ »ý¸®Åë ½ÃÀå º¸°í¼­(2025³â)
Menorrhalgia Global Market Report 2025
»óǰÄÚµå : 1730944
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

»ý¸®Åë ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR) 6.2%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 280¾ï ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£¿¡ Àü¸ÁµÇ´Â ¼ºÀåÀº ³ëÀÎ Àα¸ È®´ë, Àڱà ³» ÇÇÀӱⱸÀÇ »ç¿ë Áõ°¡, ±â¼úÀÇ Áøº¸, Àúħ½À óġ¿¡ ´ëÇÑ ±âÈ£ °íÁ¶, ¿¹¹æ ÇコÄɾ ´ëÇÑ ÁÖ¸ñ °íÁ¶ µîÀÇ ¿äÀο¡ ÀÇÇØ¼­ ÃÊ·¡µË´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿Çâ¿¡´Â Ä¡·á ¼±ÅÃÁöÀÇ ¹ßÀü, Áö¼Ó °¡´ÉÇϰí ģȯ°æÀûÀÎ Ä¡·á¿¡ ´ëÇÑ °ü½É, Ãß°¡ÀûÀÎ ±â¼úÀÇ Áøº¸, È£¸£¸ó Åõ¿© ¹æ¹ý °³¼±, Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ß µîÀÌ ÀÖ½À´Ï´Ù.

È£¸£¸ó ±ÕÇü È¥¶õÀÇ À¯º´·ü Áõ°¡´Â ¹Ì·¡ÀÇ »ý¸®Åë ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. È£¸£¸ó ±ÕÇüÀÇ È¥¶õÀº ü³» È£¸£¸óÀÌ °úÀ× ¶Ç´Â ºÎÁ·ÇØÁö¸é¼­ ÀϾ¸ç üÁßÀÇ º¯µ¿, ±âºÐÀÇ º¯È­, ÇÇ·Î, »ý½Ä¿¡ °üÇÑ ¹®Á¦ µî ´Ù¾çÇÑ °Ç°­ ¹®Á¦¸¦ ÀÏÀ¸Åµ´Ï´Ù. Çö´ëÀûÀÎ ¶óÀÌÇÁ ½ºÅ¸ÀÏ, ȯ°æ ¿µÇâ, º´¼¼ µîÀÇ ¿äÀÎÀÌ ÀÌ·¯ÇÑ ºÒ±ÕÇüÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½Ä»ýȰÀÇ È寮·¯Áü, ³ôÀº ¼öÁØÀÇ ½ºÆ®·¹½º, ¿îµ¿ ºÎÁ· µîÀº È£¸£¸óÀÇ »ý¼º°ú Á¶ÀýÀ» È寮·¯¶ß¸± °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. È£¸£¸ó ±ÕÇü È¥¶õÀº »ý¸® ÁÖ±âÀÇ Á¤»óÀûÀÎ Á¶ÀýÀ» ¹æÇØÇϰí Àڱà ȯ°æ¿¡ ¿µÇâÀ» ÁÜÀ¸·Î½á »ý¸® ÃâÇ÷Áõ(»ý¸® ´Ù·®)À» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2025³â 1¿ù ¼¼°èº¸°Ç±â±¸(WHO)´Â ´Ù³¶¼º ³­¼ÒÁõÈıºÀ» Áß´ëÇÑ °øÁߺ¸°Ç»óÀÇ ¿ì·Á·Î ´Ù·ç¸é¼­ ¸Å³â »ý½Ä ¿¬·É ¿©¼ºÀÇ 6-13%¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ±× °á°ú È£¸£¸ó ±ÕÇü È¥¶õ ¹ß»ýÀÌ Áõ°¡ÇÏ¿© »ý¸®Åë ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

»ý¸®Åë ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº È¿°úÀûÀ̰í Àå±âÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϱâ À§ÇØ È£¸£¸ó Àڱà ³» ÇÇÀӱⱸ(IUD)¿Í °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. È£¸£¸ó¼º IUD´Â Àڱà ³»¿¡ ÀåÂøÇÏ´Â ¼ÒÇü TÀÚÇü ±â±¸·Î Ȳüȣ¸£¸óÀ» ¹æÃâÇØ Àڱðæ°ü Á¡¾×À» ÁøÇÏ°Ô Çϰí Àڱ󻸷À» ¾ã°Ô ¸¸µé¾î ¹è¶õÀ» ¾ïÁ¦ÇÔÀ¸·Î½á ÀÓ½ÅÀ» ¿¹¹æÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 10¿ù µ¶ÀÏ Á¦¾àȸ»ç ¹ÙÀÌ¿¤»ç´Â ÇÇÀÓ ¹× Ư¹ß¼º »ý¸®Åë Ä¡·á¿¡ »ç¿ëµÇ´Â È£¸£¸ó¼º IUD '¹Ð·¹³ª'ÀÇ À¯·´ ±ÔÁ¦´ç±¹ÀÇ ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù. ÀÌ ÀåÄ¡´Â ·¹º¸³î°Ô½ºÆ®·¼À» Áö¼ÓÀûÀ¸·Î ¹æÃâÇϰí Àڱ󻸷À» ¾ã°Ô ¸¸µé¾î °æÇ÷·®À» ÁÙÀ̴µ¥ µµ¿òÀ» ÁÖ¸ç, ¸ÅÀÏ Åõ¾àÀ̳ª ¼ö¼úÀÌ ÇÊ¿ä ¾øÀÌ »ý¸® ´Ù·® ÃâÇ÷À» °ü¸®ÇÏ´Â ½Ç¿ëÀûÀ̰í Àå±âÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Menorrhagia, also known as menorrhalgia, refers to excessively heavy or prolonged menstrual bleeding. It is characterized by menstrual cycles lasting longer than seven days or involving blood loss greater than 80 milliliters. This condition can result in fatigue, anemia, and discomfort. Menorrhagia may be caused by factors such as hormonal imbalances, uterine fibroids, polyps, or other underlying health issues.

The primary therapeutic options for menorrhagia are hormonal and non-hormonal agents. Hormonal treatments help manage menorrhagia by regulating hormones to reduce uterine contractions, control the growth of the endometrium, and alleviate both pain and bleeding. These medications can be administered through various methods, including oral, vaginal, transdermal, intrauterine, and other routes. They are available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The menorrhalgia market research report is one of a series of new reports from The Business Research Company that provides menorrhalgia market statistics, including the menorrhalgia industry global market size, regional shares, competitors with the menorrhalgia market share, detailed menorrhalgia market segments, market trends, and opportunities, and any further data you may need to thrive in the menorrhalgia industry. This menorrhalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menorrhalgia market size has grown strongly in recent years. It will grow from $20.61 billion in 2024 to $21.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historical period can be attributed to factors such as the rising incidence of hormonal imbalances, increased awareness about menorrhalgia, a higher prevalence of gynecological disorders, the growing incidence of endometrial cancer, and better availability of over-the-counter medications.

The menorrhalgia market size is expected to see strong growth in the next few years. It will grow to $28.00 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected for the forecast period is driven by factors such as the expanding geriatric population, an increase in the use of intrauterine devices, technological advancements, a growing preference for minimally invasive procedures, and a rising focus on preventive healthcare. Key trends expected during this period include advancements in treatment options, a focus on sustainable and eco-friendly therapies, further technological progress, improvements in hormone delivery methods, and the development of innovative treatment modalities.

The increasing prevalence of hormonal imbalances is expected to drive the growth of the menorrhagia market in the future. Hormonal imbalances occur when there is an excess or deficiency of hormones in the body, leading to various health issues such as weight fluctuations, mood changes, fatigue, and reproductive problems. Factors such as modern lifestyles, environmental influences, and medical conditions contribute to these imbalances. Poor diet, high stress levels, and lack of physical activity can disrupt hormone production and regulation. Hormonal imbalances can trigger menorrhagia (heavy menstrual bleeding) by interfering with the normal regulation of the menstrual cycle and impacting the uterine environment. For instance, in January 2025, the World Health Organization highlighted polycystic ovary syndrome as a significant public health concern, affecting 6-13% of women of reproductive age annually. Consequently, the increasing occurrence of hormonal imbalances is driving market growth for menorrhagia.

Leading companies in the menorrhagia market are focusing on the development of innovative solutions, such as hormonal intrauterine devices (IUDs), to provide effective and long-term treatment options. A hormonal IUD is a small, T-shaped device placed inside the uterus that releases progestin to prevent pregnancy by thickening cervical mucus, thinning the uterine lining, and inhibiting ovulation. For example, in October 2022, Bayer AG, a German pharmaceutical company, received regulatory approval in Europe for Mirena, a hormonal IUD used for contraception and the treatment of idiopathic menorrhagia. This device continuously releases levonorgestrel, helping to reduce menstrual blood loss by thinning the uterine lining and reducing menstrual flow, offering a practical, long-term solution for managing heavy menstrual bleeding without the need for daily medication or surgery.

In January 2025, Hologic Inc., a US-based health technology company, acquired Gynesonics Inc. for an undisclosed sum. This acquisition allows Hologic to expand its portfolio of minimally invasive solutions for treating uterine fibroids and heavy menstrual bleeding, enhancing healthcare options for women. Gynesonics Inc. is a US-based medical device company specializing in systems for treating menorrhagia.

Major players in the menorrhalgia market are AbbVie Inc., Bayer HealthCare Pharmaceuticals Inc. (a division of Bayer AG), Baxter International Inc., Boston Scientific Corporation, Johns Hopkins Health System Corporation, Aegea Medical Inc., Emory Healthcare Inc., Hologic Inc., Dr. Reddy's Laboratories Ltd., Meril Life Sciences Pvt. Ltd., ASKA Pharmaceutical Holdings Co. Ltd., Ferring Pharmaceuticals Group, Minerva Infra Tech Private Limited, Roivant Sciences Ltd., Xanodyne Pharmaceuticals Inc., Pregna International Ltd., HLL Lifecare Limited, Actiza Pharmaceutical Pvt. Ltd., Wellona Pharma, OCON Healthcare Ltd.

North America was the largest region in the menorrhalgia market in 2024. The regions covered in menorrhalgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the menorrhalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The menorrhalgia market consists of revenues earned by entities by providing services such as medical consultation, diagnostic testing, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The menorrhagia market also consists of sales of products including medications, medical devices, and supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Menorrhalgia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on menorrhalgia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for menorrhalgia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The menorrhalgia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Menorrhalgia Market Characteristics

3. Menorrhalgia Market Trends And Strategies

4. Menorrhalgia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Menorrhalgia Growth Analysis And Strategic Analysis Framework

6. Menorrhalgia Market Segmentation

7. Menorrhalgia Market Regional And Country Analysis

8. Asia-Pacific Menorrhalgia Market

9. China Menorrhalgia Market

10. India Menorrhalgia Market

11. Japan Menorrhalgia Market

12. Australia Menorrhalgia Market

13. Indonesia Menorrhalgia Market

14. South Korea Menorrhalgia Market

15. Western Europe Menorrhalgia Market

16. UK Menorrhalgia Market

17. Germany Menorrhalgia Market

18. France Menorrhalgia Market

19. Italy Menorrhalgia Market

20. Spain Menorrhalgia Market

21. Eastern Europe Menorrhalgia Market

22. Russia Menorrhalgia Market

23. North America Menorrhalgia Market

24. USA Menorrhalgia Market

25. Canada Menorrhalgia Market

26. South America Menorrhalgia Market

27. Brazil Menorrhalgia Market

28. Middle East Menorrhalgia Market

29. Africa Menorrhalgia Market

30. Menorrhalgia Market Competitive Landscape And Company Profiles

31. Menorrhalgia Market Other Major And Innovative Companies

32. Global Menorrhalgia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Menorrhalgia Market

34. Recent Developments In The Menorrhalgia Market

35. Menorrhalgia Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â